Results 171 to 180 of about 41,377 (182)

Senescence as a main mechanism of Ritonavir and Ritonavir‐NO action against melanoma

Molecular Carcinogenesis, 2019
Yousef Al-Abed, Katia Mangano, Sanja Mijatović   +2 more
exaly  

Ritonavir

2018
openaire   +1 more source

Discontinuation Rates for Protease Inhibitor Regimens Containing Ritonavir 600 mg versus Ritonavir 400 mg Plus Saquinavir 400 mg

Annals of Pharmacotherapy, 1999
Joseph Eron, Ralph H Raasch, J D Butts
exaly  

Evidence for Time-Dependent Interactions between Ritonavir and Lopinavir/Ritonavir Plasma Levels Following P-Glycoprotein Inhibition in Sprague-Dawley Rats

Biological and Pharmaceutical Bulletin, 2011
Michelle Viljoen, Malie Rheeders
exaly  

Ritonavir-boosted protease inhibitors in HIV therapy

Annals of Medicine, 2011
, Mark Hull
exaly  

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

Lancet, The, 2008
Juan Echevarría, Jean-Michel Molina, Jaime Federico Andrade-Villanueva   +2 more
exaly  

Population pharmacokinetics of lopinavir in combination with ritonavir in HIV‐1‐infected patients

British Journal of Clinical Pharmacology, 2005
exaly  

Ritonavir

Reactions Weekly, 2014
openaire   +1 more source

Dose‐Related Reduction in Bupropion Plasma Concentrations by Ritonavir

Journal of Clinical Pharmacology, 2010
exaly  

??? and with ritonavir

Inpharma Weekly, 1998
openaire   +1 more source